Screening and diagnosis

Classification and risk stratification

Perioperative care

Quality improvement

Patient education

Nonpharmacologic interventions

Therapeutic procedures

Respiratory support

Follow-up and surveillance

Specific circumstances

Preventative measures

Medical management

Surgical interventions

Inpatient care

Diagnostic procedures

Diagnostic investigations

Insufficient evidence to make a recommendation.

Strongly favor this test or intervention.

The Revised International Prognostic Scoring System (IPSS-R) calculator for myelodysplastic syndrome evaluates several clinical parameters to determine a patient's prognosis, providing both a numerical score and an interpretation of their risk group and median survival. The input parameters analyzed by the calculator are:

1. Cytogenetic group
2. Medullary blasts percentage
3. Hemoglobin levels in g/dL
4. Platelet count per mm³
5. Absolute neutrophil count per mm³

Each of these inputs is assigned a score based on specific criteria, which are then summed to yield a total prognostic score. The scoring system for each input is detailed as follows:

- Cytogenetic group scores range from 0 to 4 based on the complexity and nature of chromosomal abnormalities.
- Medullary blasts percentage is scored from 0 to 3 depending on the percentage of blasts present.
- Hemoglobin levels are scored as 0, 1, or 1.5 depending on the concentration of hemoglobin.
- Platelet count is scored as 0, 0.5, or 1 based on the number of platelets per mm³.
- Absolute neutrophil count scores are either 0 or 0.5, determined by the neutrophil count.

The cumulative score is computed by summing the individual scores associated with each input parameter. This total score, ranging from 0 to a maximum of 10, is used to categorize patients into distinct risk groups, each associated with a different median survival expectation:

- A score of 1.5 or below indicates a "Very low risk group" with a median survival of 8.8 years.
- A score between 1.5 and 3 falls into the "Low risk group" with a median survival of 5.3 years.
- A score between 3 and 4.5 corresponds to an "Intermediate risk group" with a median survival of 3 years.
- Scores between 4.5 and 6 designate the "High risk group" with a median survival of 1.6 years.
- Any score above 6 places the patient in the "Very high risk group," with a median survival of 0.8 years.

The Revised International Prognostic Scoring System (IPSS-R) is a clinical calculator used specifically for patients diagnosed with myelodysplastic syndrome (MDS). The IPSS-R is an updated version of the original International Prognostic Scoring System (IPSS), and it provides a more accurate risk stratification of MDS patients. 

The IPSS-R is used to predict the overall survival and risk of transformation to acute myeloid leukemia (AML) in patients with MDS. It takes into account five different factors: cytogenetics, bone marrow blast percentage, and levels of hemoglobin, platelets, and absolute neutrophil count. 

The IPSS-R is not applicable to patients with therapy-related MDS or those who have already progressed to AML. It is also less accurate in patients who have received prior treatment for MDS. The IPSS-R is a valuable tool for clinicians to guide treatment decisions and discuss prognosis with patients.

Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome

The International Prognostic Scoring System (IPSS) for myelodysplastic syndrome provides an assessment of a patient's prognosis by analyzing three key inputs: cytogenetic abnormalities, medullary blast percentage, and the number of cytopenias. Each of these factors is assigned a score that accumulates to form an overall risk score.

For the cytogenetic group:

- Normal karyotype, del5q), del20q) = 0 points
- ≥ 3 abnormalities or abnormal chromosome 7 = 1 point
- Other abnormalities = 0.5 points

In terms of medullary blasts percentage:

- ≤ 5% = 0 points
- 5-10% = 0.5 points
- (Note: The option for 11-20% is not explicitly included in the inputs but would logically align with a higher score)
- 21-30% = 2 points

For the number of cytopenias (considering anemia, neutropenia, and thrombocytopenia):

- None or 1 = 0 points
- 2 or 3 = 0.5 points

The total score is calculated by summing the points from each of the input categories. Based on this total score, the interpretation of risk is categorized as follows:

- A total score of 0 suggests a low risk.
- Scores ranging from 0.5 to 2 indicate an intermediate risk level.
- A score of 2.5 or above signifies a high risk of myelodysplastic syndrome progression.

This tool systematically guides healthcare providers in assessing the risk profile of a patient with myelodysplastic syndrome, thereby aiding in the management and therapeutic decisions.

The International Prognostic Scoring System (IPSS) is a clinical calculator used for the prognosis of patients with myelodysplastic syndrome (MDS). MDS is a group of disorders characterized by poorly formed blood cells or cells that do not work properly. The IPSS is used to predict the risk of progression to acute myeloid leukemia (AML) and overall survival in newly diagnosed MDS patients. 

The IPSS takes into account factors such as the number of cytopenias (low counts of one or more types of blood cells), the percentage of bone marrow blasts (immature cells), and the type of chromosomal abnormalities. Based on these factors, patients are categorized into four risk groups: low, intermediate-1, intermediate-2, and high. 

The IPSS is not applicable to patients with secondary MDS (MDS that develops as a result of treatment for another disease or exposure to certain chemicals), or those who have already progressed to AML. It is also less accurate in patients who have received prior therapy for MDS.

Cancer-related anemia

Guidelines

Key sources

Diagnostic investigations

Medical management

Therapeutic procedures

Specific circumstances